Bridget Bagert, MD
Neurology · New Orleans, LANPI 1174589824
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by EMD Serono, Inc. at 38.0% of the total. 2025 is the largest year on record at $98,777, more than ten times the $138 reported in 2019. Among neurology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $1457.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$75K
- Sanofi$53K
- TG Therapeutics, Inc.$50K
- Amgen$9K
- Genentech USA, Inc.$6K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $248 from 3 others
Across 378 payments — averaging $3052.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$360K
- Genentech, Inc.$276K
- AbbVie$235K
- Roche Products Limited$135K
- Biogen$72K
- Jazz Pharmaceuticals Inc.$62K
- plus $15K from 1 others
What the payments were for
- Consulting fees$58,06729%
- Speaking & faculty fees$118,20360%
- Travel & lodging$18,1669%
- Food & beverage$3,6472%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 45 | $75,321 |
| Sanofi | 24 | $52,823 |
| TG Therapeutics, Inc. | 43 | $50,371 |
| Amgen | 8 | $8,778 |
| Genentech USA, Inc. | 8 | $6,226 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,430 |
| Biogen | 3 | $119 |
| Boston Scientific | 1 | $112 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$71,594
- BRIUMVI$49,845
- UPLIZNA$8,605
- OCREVUS$6,071
- SPECTRA WAVEWRITER$112
How this compares
$198,197 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 62 | $562,147 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 41 | $361,968 |
| CopaxoneGlatiramer Acetate | 37 | $222,905 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 18 | $208,970 |
| Avonex (4 Pack)Interferon Beta-1a | 24 | $205,194 |
| Plegridy PenPeginterferon Beta-1a | 12 | $94,792 |
| GlatopaGlatiramer Acetate | 21 | $81,479 |
| Glatiramer Acetate | 28 | $53,519 |
| MyrbetriqMirabegron | 62 | $43,531 |
| Teriflunomide | 41 | $35,142 |
| Dalfampridine ErDalfampridine | 18 | $7,681 |
| Dimethyl Fumarate | 18 | $7,531 |
| FingolimodFingolimod Hcl | 16 | $6,452 |
| Mycophenolate Mofetil | 26 | $4,249 |
| Gabapentin | 177 | $3,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $119 | $205,19424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.
Other neurology in New Orleans
- John EnglandNew Orleans$268K
- Brian CopelandNew Orleans$211K
- Sheryl Martin-SchildNew Orleans$106K
- Piotr OlejniczakNew Orleans$82K
- Elizabeth CrabtreeNew Orleans$36K
- Caroline GoldinNew Orleans$36K
- Jesus LoveraNew Orleans$27K
- Julia StaischNew Orleans$22K
- Pooja Mohan RaoNew Orleans$17K
- Ronald FioreNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.